China's Abogen, a small mRNA upstart, sets a biotech record with mammoth $700M Series C
Summary
A lit\xadtle-known start\xadup from Chi\xadna shocked the biotech world Thurs\xadday with a record-break\xading Se\xadries C, show\xading how deep-pock\xadet\xaded in\xadvestors are an\xadgling to get a piece of the mR\xadNA vac\xadcine pie.Abo\xadgen Bio\xadsciences closed a stag\xadger\xading $700 mil\xadlion round Thurs\xadday, the com\xadpa\xadny an\xadnounced, large\xadly to push for\xadward its mR\xadNA-based Covid-19 vac\xadcine can\xaddi\xaddate. But the funds will al\xadso help the Suzhou, Chi\xadna-based biotech vast\xadly ex\xadpand its oth\xader vac\xadcine and on\xadcol\xado\xadgy pro\xadgrams, while build\xading out its man\xadu\xadfac\xadtur\xading ca\xadpa\xadbil\xadi\xadties to sup\xadport those ef\xadforts.Unlock this article instantly by becoming a free subscriber. Youll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.